Capitol Health (ASX:CAJ) said the Federal Court of Australia will hear on Dec. 4 its application seeking the approval of the scheme of arrangement relating to its proposed merger with Integral Diagnostics (ASX:IDX), according to a Tuesday filing with the Australian bourse.
This second court hearing is subject to Capitol shareholders approving the scheme by the requisite majorities on Dec. 2, the filing said.
Capitol Health's shares were down nearly 3% in recent Tuesday trade, while Integral Diagnostics' shares fell 1%.
Price (AUD): $0.37, Change: $-0.01, Percent Change: -2.63%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。